EXENS Exosens
Exosens, together with its subsidiaries, develops, manufactures, and sells electro-optical technologies in France, Europe, North America, Asia, and internationally. It operates in two segments, Amplification and Detection and Imaging. The company offers image intensifier tubes; cameras, sensors, modules and cores, and imaging systems and solutions, including UV missile warning solution, atmospheric sounder, and spectroradiometer; and detection and imaging products for ions and electrons, photons, and neutrons, as well as micro pore optics and components, such as phosphor screens, resistive glass products, microchannel plates, and electron generator arrays. It also provides bare and energy compensated Geiger- Müller tubes; gamma and neutron detectors; mineral insulated extensions; and silicon photodiodes, as well as methane airborne detection solutions. The company sells its products under the Exosens, Photonis, Xenics, Telops, El-Mul, and Noxant brand names. It serves defense and surveillance, life sciences and environment, industrial control, and nuclear markets. The company was founded in 1937 and is headquartered in Mérignac, France.…
Industry Peers
Aerospace & DefenseKey Statistics
About Exosens (EPA: EXENS)
›
Exosens (EPA: EXENS) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Aerospace & Defense industry, part of the Industrials sector, and reports about 2,000 employees.
The shares were at 52.55 EUR on 19 November 2026, up 24.2% over 52 weeks. Its 52-week range is 40.00 EUR to 74.00 EUR: the price is 29.0% below the high and 31.4% above the low.
At a market capitalisation of 2.66B EUR, it trades at 125.1 times trailing earnings and 21.5 times forward earnings. The median trailing P/E of its 19 largest Aerospace & Defense peers is 31.3, a premium of 299% for EXENS. It pays a dividend yielding 0.58% (it pays out 77% of its earnings), against a median of 1.55% among the dividend payers in that peer group.
Exosens reports return on equity of 6.9%, an operating margin of 17.4% and revenue up 15.3% year over year.
Its debt exceeds its cash by 200.24M EUR, a debt-to-equity ratio of 0.04. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 10 analysts cover the stock, with an average rating of Buy; their mean price target of 69.85 EUR is 32.9% above the current price. The next earnings report is expected on 22 February 2027.